Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLVE-DVT: Hydroxyethylrutoside for DVT Resolution
NCT04670432Phase 3Completed
- Sponsor
- Maastricht University Medical Center+
- Start
- Dec 2020
- Primary completion
- Nov 2023
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of hydroxyethylrutoside in deep vein thrombosis (DVT), post-thrombotic syndrome (PTS), sponsored by Maastricht University Medical Center+. Started Dec 2020; status: completed.
02
Drugs
hydroxyethylrutoside
03
Conditions
deep vein thrombosis (DVT)post-thrombotic syndrome (PTS)
Beyond the preview
Go deeper on NCT04670432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04670432.